Conduit Pharmaceuticals Stock Net Income
| CDT Stock | 0.09 0.01 7.61% |
Conduit Pharmaceuticals fundamentals help investors to digest information that contributes to Conduit Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Conduit Stock. The fundamental analysis module provides a way to measure Conduit Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Conduit Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -535 K | -561.8 K | |
| Net Loss | -4.4 M | -4.6 M | |
| Net Loss | -535 K | -561.8 K | |
| Net Loss | (0.01) | (0.01) |
Conduit |
Conduit Pharmaceuticals Company Net Income Analysis
Conduit Pharmaceuticals' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Conduit Pharmaceuticals Net Income | (535 K) |
Most of Conduit Pharmaceuticals' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Conduit Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Conduit Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Conduit Pharmaceuticals reported net income of (535,000). This is 100.16% lower than that of the Life Sciences Tools & Services sector and 100.76% lower than that of the Health Care industry. The net income for all United States stocks is 100.09% higher than that of the company.
Conduit Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Conduit Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Conduit Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Conduit Pharmaceuticals by comparing valuation metrics of similar companies.Conduit Pharmaceuticals is currently under evaluation in net income category among its peers.
Conduit Fundamentals
| Return On Asset | -3.22 | ||||
| Current Valuation | 9.44 M | ||||
| Shares Outstanding | 100.77 M | ||||
| Shares Owned By Insiders | 49.11 % | ||||
| Shares Owned By Institutions | 4.05 % | ||||
| Number Of Shares Shorted | 3.57 M | ||||
| EBITDA | (324 K) | ||||
| Net Income | (535 K) | ||||
| Total Debt | 985 K | ||||
| Book Value Per Share | (0.01) X | ||||
| Cash Flow From Operations | (7.72 M) | ||||
| Short Ratio | 0.14 X | ||||
| Earnings Per Share | (0.08) X | ||||
| Beta | 2.12 | ||||
| Market Capitalization | 8.61 M | ||||
| Total Asset | 7.22 M | ||||
| Retained Earnings | (11.3 M) | ||||
| Working Capital | 3.93 M | ||||
| Net Asset | 7.22 M |
About Conduit Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Conduit Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Conduit Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Conduit Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Conduit Stock Analysis
When running Conduit Pharmaceuticals' price analysis, check to measure Conduit Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Conduit Pharmaceuticals is operating at the current time. Most of Conduit Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Conduit Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Conduit Pharmaceuticals' price. Additionally, you may evaluate how the addition of Conduit Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.